Urinary Tract Infection News and Research

RSS

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p<0.005) in improving overall sleep efficiency at night one and at the end of week four in patients with primary insomnia. MK-4305 was generally well-tolerated in the study. Orexins are neuropeptides (chemical messengers) that are released by specialized neurons in the hypothalamus region of the brain and are believed to be an important regulator of the brain's sleep-wake process.

9 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

NovaBay first-quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported financial results for the first quarter of 2010.

12 May 2010

MBPs offer no clinical benefit to patients undergoing PD: Research team

Mechanical bowel preparations are commonly administered preoperatively to patients who undergo a pancreaticoduodenectomy (Whipple procedure) to treat benign and malignant tumors of the pancreas, common bile duct or duodenum. MBPs are employed as a preventative measure in gastrointestinal surgery but their effectiveness in reducing perioperative infectious complications remains unclear.

7 May 2010

Implementation of quality improvement intervention reduces medication use in premature babies: Study

A new study by Pediatrix Medical Group researchers has found that the implementation of a quality improvement intervention significantly reduces the use of a large number of medications in premature babies across a broad neonatal intensive care network.

3 May 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Fever in kids underestimated by Doctors: new study

In a new study researchers have found that some physicians may be missing the seriousness of an infection in a child presenting with fever. The study published in the British Medical Journal involved 16,000 children from 2004 to 2006 with fever and found that doctors could not diagnose up to one third of the potentially life-threatening illnesses in these children.

27 Apr 2010

GBS serotype III more commonly associated with urinary tract infections

Research suggests pathogenic strains of Group B Streptococcus (GBS) are an under-recognised cause of urinary tract infections.

24 Apr 2010

International Day for Fighting Infection focuses on hospital infection control

Hospital acquired infections are the focus for the 3rd International Day for Fighting Infection, being marked on St. George’s Day, as experts meet to look at the evolution of infection control in hospitals.

22 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Bacterial infections often missed in febrile children in the ER

In a new study researchers reveal that up to one third of children with fever due to bacterial infections do not receive antibiotics in the emergency department and 20% of kids receive antibiotics unnecessarily.

22 Apr 2010

Computerised diagnostic model outperforms clinical judgement for diagnosing children with febrile illness

A computerised diagnostic model outperforms clinical judgement for the diagnosis of fever in young children, and may improve early treatment, finds a study published on bmj.com today.

21 Apr 2010

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

19 Apr 2010

Kidney expert receives international award

Professor Jonathan Craig from the School of Public Health has been honoured for his contribution to the study of kidney disease. The US-based National Kidney Foundation awarded Professor Craig with its 2010 International Distinguished Medal, recognising outstanding accomplishments in the field of nephrology.

16 Apr 2010

AHRQ: Women accounted for nearly 60% of 39.4M admissions to U.S. hospitals in 2007

Women accounted for nearly 60 percent of the 39.4 million admissions to U.S. hospitals in 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

7 Apr 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

Expert testimony in trial of Dr Patel

Dr Jayant Patel’s manslaughter trial in the supreme court of Brisbane saw Dr Nigel Chikolwa give testimony about the deteriorating condition of Mr Morris after surgery. Dr Chikolwa was the principal house officer at Bundaberg hospital, where Dr Patel had performed the surgery in 2003.

25 Mar 2010

Urinary Tract Infection News and Research

Further Reading

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Amgen announces European approval of Prolia

NovaBay first-quarter net loss increases to $1.6 million

MBPs offer no clinical benefit to patients undergoing PD: Research team

Implementation of quality improvement intervention reduces medication use in premature babies: Study

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Fever in kids underestimated by Doctors: new study

GBS serotype III more commonly associated with urinary tract infections

International Day for Fighting Infection focuses on hospital infection control

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Bacterial infections often missed in febrile children in the ER

Computerised diagnostic model outperforms clinical judgement for diagnosing children with febrile illness

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Kidney expert receives international award

AHRQ: Women accounted for nearly 60% of 39.4M admissions to U.S. hospitals in 2007

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

Expert testimony in trial of Dr Patel

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News